This narrative review summarizes histiotype-specific management of adult soft-tissue sarcomas, covering extremity/truncal and retroperitoneal disease. It addresses surgery, radiation sequencing, and chemotherapy in the context of personalized medicine. The review draws on landmark trials, large registry studies, and consensus guidelines to provide an evidence-based framework for multidisciplinary sarcoma care.
Every patient with a deep soft-tissue mass or any retroperitoneal tumor should be referred to a specialized sarcoma center before any excision — unplanned nononcologic excisions affect roughly 30% of extremity STS patients and increase morbidity even when OS is preserved.
When counseling an extremity STS patient on radiation timing, frame the decision around age and comorbidity burden. Preoperative radiation gives you a 90% R0 rate and better long-term limb function, but a 35% acute wound complication rate. A younger, fit patient tolerates the wound risk better than years of fibrosis and stiffness; an older patient with comorbidities may not.
For retroperitoneal sarcoma, resist the impulse to add radiation or chemotherapy routinely. STRASS-1 showed no survival benefit from neoadjuvant radiation overall. Perioperative chemotherapy in a large NCDB study was associated with worse OS. Both interventions require histiotype-specific discussion at a multidisciplinary tumor board, and neither should be applied by default.
The one intervention with unambiguous retroperitoneal benefit is achieving macroscopic complete resection at first operation. Extended compartmental resection cuts 5-year local recurrence nearly in half (29% vs 48%). And locoregional recurrence drives 75% of RPS-related deaths, making the index operation the single most important event in a patient's disease course.
This narrative review summarizes histiotype-specific management of adult soft-tissue sarcomas, covering extremity/truncal and retroperitoneal disease. It addresses surgery, radiation sequencing, and chemotherapy in the context of personalized medicine. The review draws on landmark trials, large registry studies, and consensus guidelines to provide an evidence-based framework for multidisciplinary sarcoma care.
Every patient with a deep soft-tissue mass or any retroperitoneal tumor should be referred to a specialized sarcoma center before any excision — unplanned nononcologic excisions affect roughly 30% of extremity STS patients and increase morbidity even when OS is preserved.
When counseling an extremity STS patient on radiation timing, frame the decision around age and comorbidity burden. Preoperative radiation gives you a 90% R0 rate and better long-term limb function, but a 35% acute wound complication rate. A younger, fit patient tolerates the wound risk better than years of fibrosis and stiffness; an older patient with comorbidities may not.
For retroperitoneal sarcoma, resist the impulse to add radiation or chemotherapy routinely. STRASS-1 showed no survival benefit from neoadjuvant radiation overall. Perioperative chemotherapy in a large NCDB study was associated with worse OS. Both interventions require histiotype-specific discussion at a multidisciplinary tumor board, and neither should be applied by default.
The one intervention with unambiguous retroperitoneal benefit is achieving macroscopic complete resection at first operation. Extended compartmental resection cuts 5-year local recurrence nearly in half (29% vs 48%). And locoregional recurrence drives 75% of RPS-related deaths, making the index operation the single most important event in a patient's disease course.